

## Correction

### Correction to “Canadian Cardiovascular Harmonized National Guideline Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2022 update”

*CMAJ* has been made aware of errors that occurred in the C-CHANGE guideline published in the Nov. 7, 2022, issue.<sup>1</sup>

In the “People with obesity, diabetes or hypertension” section on page E1467, glucagon-like peptide-1 (GLP1)-receptor antagonists were listed as therapy to aid with weight loss. This should have read “glucagon-like peptide-1 (GLP1)-receptor agonists.”

In the “Affiliations” section on page E1480, a person who is not an author was inadvertently listed. The following entry has now been removed: “Office of Nutrition Policy Promotion (Aziz), Health Canada, Ottawa, Ont.”

This has been corrected at [cmaj.ca](http://cmaj.ca).

■ Cite as: *CMAJ* 2022 December 19;194: E1694.doi: 10.1503/cmaj.221674

### Reference

1. Jain R, Stone JA, Agarwal G, et al. Canadian Cardiovascular Harmonized National Guideline Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2022 update. *CMAJ* 2022;194:E1460-80.